Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Acta Psychiatr Scand. 2013 Jul;128(1):70-7. doi: 10.1111/acps.12004. Epub 2012 Sep 4.
To explore the prevalence and discontinuation of dispensed medications for attention deficit/hyperactivity disorder (ADHD) drugs from 2006 to 2009.
A total population cohort of all individuals aged 6-45 years, alive and registered as residents in Sweden during any calendar year from 2006 to 2009 (N = 5 149 791) included 41 700 patients dispensed with an ADHD drug (methylphenidate, atomoxetine, amphetamine, or dexamphetamine). The dispensing prevalence was calculated for each year, stratified on sex and age. A longitudinal analysis was also performed to compare the rates of treatment discontinuation across the strata.
The dispensing prevalence increased from 2.93 per 1000 in 2006 to 6.98 in 2009 (PR = 2.38, 95% CI = 2.34-2.43). The prevalence ratio (PR) was 3.40 for adults, 22-45 years old; 2.41 for adolescents, 15-21 years old; and 1.90 for children aged 6-14. The increase was also greater in women than in men (PR = 2.92 vs. 2.19). Patients aged 15-21 were the most likely to discontinue treatment; after 3 years and 11 months, 27% of those patients were still under treatment.
From 2006 to 2009, the number of prescriptions dispensed for ADHD drugs increased substantially. The rate of treatment discontinuation in the age interval 15-21 is higher than expected considering the persistence rates of the disorder.
探讨 2006 年至 2009 年注意力缺陷/多动障碍(ADHD)药物的配药率及其停药率。
本研究纳入了 2006 年至 2009 年期间,瑞典年龄在 6-45 岁之间的所有在世人群(n=5149791 人),其中 41700 人被诊断为 ADHD 并开 ADHD 药物(哌醋甲酯、托莫西汀、安非他命或右旋苯丙胺)。每年按性别和年龄分层计算 ADHD 药物的配药率。还进行了纵向分析,比较了各分层中停药率的差异。
2006 年 ADHD 药物的配药率为 2.93/1000,到 2009 年增加至 6.98/1000(PR=2.38,95%CI=2.34-2.43)。成年患者(22-45 岁)的比值比(PR)为 3.40,青少年(15-21 岁)为 2.41,儿童(6-14 岁)为 1.90。女性的增长幅度也高于男性(PR=2.92 vs. 2.19)。15-21 岁患者最有可能停止治疗,经过 3 年 11 个月后,仍有 27%的患者在接受治疗。
2006 年至 2009 年,ADHD 药物的处方数量显著增加。考虑到该疾病的持续率,15-21 岁年龄组的停药率高于预期。